IQVIA (NYSE:IQV) Upgraded by Jefferies Financial Group to Buy Rating

Jefferies Financial Group upgraded shares of IQVIA (NYSE:IQV) from a hold rating to a buy rating in a report published on Tuesday morning, Marketbeat.com reports. The firm currently has $225.00 price target on the medical research company’s stock, up from their previous price target of $195.00.

Several other research analysts have also recently weighed in on IQV. Mizuho upped their price target on shares of IQVIA from $190.00 to $225.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Citigroup reiterated a “neutral” rating on shares of IQVIA in a report on Thursday, May 22nd. William Blair reiterated an “outperform” rating on shares of IQVIA in a report on Wednesday, July 23rd. Barclays boosted their price objective on shares of IQVIA from $165.00 to $185.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 23rd. Finally, Truist Financial boosted their price objective on shares of IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a research report on Wednesday, July 23rd. Eighteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $229.64.

IQVIA Stock Up 1.2%

IQVIA stock opened at $189.89 on Tuesday. The stock has a market capitalization of $32.28 billion, a PE ratio of 27.48, a price-to-earnings-growth ratio of 2.06 and a beta of 1.32. IQVIA has a twelve month low of $134.65 and a twelve month high of $248.03. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The company has a 50 day moving average of $181.03 and a 200-day moving average of $167.36.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to analysts’ expectations of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, equities research analysts anticipate that IQVIA will post 10.84 EPS for the current fiscal year.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the company’s stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the company’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

Institutional Trading of IQVIA

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. American National Bank & Trust bought a new stake in IQVIA during the first quarter worth $26,000. Clal Insurance Enterprises Holdings Ltd raised its position in IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after acquiring an additional 131 shares in the last quarter. Golden State Wealth Management LLC raised its position in IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock worth $31,000 after acquiring an additional 130 shares in the last quarter. AllSquare Wealth Management LLC bought a new stake in IQVIA during the first quarter worth $33,000. Finally, ST Germain D J Co. Inc. raised its position in IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock worth $34,000 after acquiring an additional 76 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.